Edgewise stock holds Buy rating, $50 target from Truist Securities

On Wednesday, Truist Securities maintained a Buy rating and a $50.00 price target on Edgewise Therapeutics (NASDAQ:EWTX), currently trading at $16.06 with a market capitalization of $1.5 billion. According to InvestingPro data, the stock has declined nearly 25% year-to-date, suggesting potential opportunity given the analyst’s bullish stance. The focus was on EDG-7500, a treatment with the potential to significantly reduce LVOT-G/pro-BNP levels—a marker of heart disease—without causing left ventricular ejection fraction (LVEF) complications. The analyst noted that despite robust efficacy data, investor sentiment seemed to be negatively impacted by concerns about atrial fibrillation (AF) occurrences during the trial.

The analyst addressed these concerns by highlighting that AF is a pre-existing condition in hypertrophic cardiomyopathy (HCM) patients, the population studied in the Phase 2 CIRRUS trial. They pointed out that the lack of a placebo control in the trial made it challenging to determine if the AF rates were related to the drug. Additionally, a post-hoc analysis showed that half of the reported AF cases did not meet the study criteria. The analyst also mentioned that HCM-treating cardiologists are accustomed to managing AF occurrences.

Despite these AF concerns, the analyst believes that EDG-7500’s efficacy profile remains promising. The treatment has shown no increased risk of LVEF complications, which could position it as a competitive option for various cardiovascular diseases. InvestingPro analysis shows the company maintains a strong financial position with a current ratio of 19.93 and minimal debt, providing ample resources to advance its clinical programs. Get access to the comprehensive Pro Research Report for deeper insights into EWTX’s financial health and growth potential. The analyst’s confidence in the drug’s potential efficacy is also based on the expectation of multiple upcoming catalysts throughout the year.

Truist Securities’ reiteration of the Buy rating suggests that they view the recent stock movement, which seems to discount the value of the EDG-7500 program, as an overreaction. They continue to support the drug’s development and anticipate that it could offer favorable outcomes for patients without the added risk of LVEF complications.

The company is expected to continue advancing the EDG-7500 program, with the analyst looking forward to the catalysts that could further demonstrate the drug’s potential and address the concerns that have recently affected investor sentiment. With analyst price targets ranging from $30 to $56 and a notably low beta of 0.23, EWTX offers an interesting opportunity for investors seeking biotechnology exposure with relatively lower volatility. Discover more exclusive insights and real-time analysis with InvestingPro.

In other recent news, Cytokinetics (NASDAQ:CYTK) has been in the spotlight following developments in the biopharmaceutical sector. Morgan Stanley (NYSE:MS) maintained its Overweight rating on Cytokinetics with a $67 price target, highlighting the safety profile of its drug aficamten compared to Edgewise Therapeutics’ EDG-7500. The analysis by Morgan Stanley indicated that aficamten showed no significant difference in atrial fibrillation occurrence compared to placebo, a point that could influence its market performance. Meanwhile, Edgewise Therapeutics reported results from its Phase 2 trial of EDG-7500 for hypertrophic cardiomyopathy, noting some adverse events, including atrial fibrillation, which prompted investor concerns.

Edgewise’s stock experienced a significant decline following these trial results and the announcement of a $200 million stock offering. The offering, priced at $20.13 per share, aims to fund various initiatives, including the advancement of clinical trials and potential commercial launches. Despite the setbacks, Edgewise’s trial results showed promise in reducing left ventricular outflow tract gradients and improving cardiac biomarkers. Analysts from RBC have mixed views, with some concerns about the safety profile but acknowledging the potential market positioning of Cytokinetics. These developments underscore the competitive dynamics in the biotech industry, where trial outcomes and safety profiles significantly impact company prospects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.